Drugs / HIP2101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04967014 | May → Jun 2021 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIP2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04967014 ↗ |
| Route | Oral | “After Oral Administration of HIP2101” NCT04967014 ↗ |